Boratyńska M, Boratyński J, Magott M, Szewczyk Z
Z Katedry i Kliniki Nefrologii, Akademii Medycznej we Wrocławiu, Z Instytutu Immunologii i Terapii, Doświadczalnej PAN we Wrocławiu.
Przegl Lek. 1996;53(5):398-401.
In order to assess the effect of erythropoietin (Epo) treatment on amino acids profile in hemodialysis patients (HD pts) 2 groups of pts were analyzed: I-12 pts HD for 146 +/- 71 months, Epo treated for 64 +/- 10 months, II-17 pts HD for 120 +/- 39 months, non Epo treated, mean Hb 11.5 +/- 1.2 g/dl. Controls consisted of 11 healthy individuals. Amino acids were estimated by HPLC OPA method. In group I blood levels of leucine (p < 0.03), valine (p < 0.002) were decreased and alanine (p < 0.05) was increased when compared to controls. In this group, blood levels of methionine, tyrosine and asparagine were elevated (p < 0.04) when compared to group II but they were lower (about 30%) then in controls. In group II pts showed reduced levels of valine (p < 0.008), leucine (p < 0.001), methionine (p < 0.0001), tyrosine (p < 0.003), asparagine (p < 0.04), whereas serine, glutamate and alanine (p < 0.04) were increased when compared to controls. Essential to nonessential amino acids ratios in group I, II and controls were as follows: 0.17; 0.12; 0.49 respectively. There were not substantial differences in amino acids in pts with elevated or normal PTH level in both HD groups. Long term EPO treatment only partially corrected changes in amino acids levels in pts with chronic renal failure.
为了评估促红细胞生成素（Epo）治疗对血液透析患者（HD患者）氨基酸谱的影响，分析了2组患者：I组-12例HD患者，透析146±71个月，接受Epo治疗64±10个月；II组-17例HD患者，透析120±39个月，未接受Epo治疗，平均血红蛋白为11.5±1.2g/dl。对照组由11名健康个体组成。采用高效液相色谱OPA法测定氨基酸。与对照组相比，I组中亮氨酸（p<0.03）、缬氨酸（p<0.002）的血药浓度降低，丙氨酸（p<0.05）升高。与II组相比，该组中甲硫氨酸、酪氨酸和天冬酰胺的血药浓度升高（p<0.04），但比对照组低（约30%）。与对照组相比，II组患者的缬氨酸（p<0.008）、亮氨酸（p<0.001）、甲硫氨酸（p<0.0001）、酪氨酸（p<0.003）、天冬酰胺（p<0.04）水平降低，而丝氨酸、谷氨酸和丙氨酸（p<0.04）升高。I组、II组和对照组中必需氨基酸与非必需氨基酸的比例分别为：0.17；0.12；0.49。两组HD患者中甲状旁腺激素水平升高或正常的患者，其氨基酸水平无显著差异。长期EPO治疗仅部分纠正了慢性肾衰竭患者氨基酸水平的变化。
